vs

Side-by-side financial comparison of Blue Bird Corp (BLBD) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $333.1M, roughly 1.9× Blue Bird Corp). Royalty Pharma plc runs the higher net margin — 34.4% vs 9.2%, a 25.2% gap on every dollar of revenue. On growth, Blue Bird Corp posted the faster year-over-year revenue change (6.1% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -1.9%).

The Blue Bird Corporation is an American bus manufacturer. Headquartered in Fort Valley, Georgia, the company was best known for its production of school buses. The company has also manufactured a wide variety of other bus types, including transit buses, motorhomes, and specialty vehicles such as mobile libraries and mobile police command centers.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

BLBD vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.9× larger
RPRX
$622.0M
$333.1M
BLBD
Growing faster (revenue YoY)
BLBD
BLBD
+1.3% gap
BLBD
6.1%
4.8%
RPRX
Higher net margin
RPRX
RPRX
25.2% more per $
RPRX
34.4%
9.2%
BLBD
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-1.9%
BLBD

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BLBD
BLBD
RPRX
RPRX
Revenue
$333.1M
$622.0M
Net Profit
$30.8M
$214.2M
Gross Margin
21.4%
Operating Margin
11.3%
62.4%
Net Margin
9.2%
34.4%
Revenue YoY
6.1%
4.8%
Net Profit YoY
7.1%
2.9%
EPS (diluted)
$0.94
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLBD
BLBD
RPRX
RPRX
Q4 25
$333.1M
$622.0M
Q3 25
$409.4M
$609.3M
Q2 25
$398.0M
$578.7M
Q1 25
$358.9M
$568.2M
Q4 24
$313.9M
$593.6M
Q3 24
$350.2M
$564.7M
Q2 24
$333.4M
$537.3M
Q1 24
$345.9M
$568.0M
Net Profit
BLBD
BLBD
RPRX
RPRX
Q4 25
$30.8M
$214.2M
Q3 25
$36.5M
$288.2M
Q2 25
$36.5M
$30.2M
Q1 25
$26.0M
$238.3M
Q4 24
$28.7M
$208.2M
Q3 24
$24.7M
$544.0M
Q2 24
$28.7M
$102.0M
Q1 24
$26.0M
$4.8M
Gross Margin
BLBD
BLBD
RPRX
RPRX
Q4 25
21.4%
Q3 25
21.1%
Q2 25
21.6%
Q1 25
19.7%
Q4 24
19.2%
Q3 24
17.0%
Q2 24
20.8%
Q1 24
18.4%
Operating Margin
BLBD
BLBD
RPRX
RPRX
Q4 25
11.3%
62.4%
Q3 25
12.3%
70.1%
Q2 25
12.6%
36.3%
Q1 25
9.4%
94.0%
Q4 24
10.5%
60.9%
Q3 24
7.3%
Q2 24
11.9%
50.2%
Q1 24
10.4%
-13.0%
Net Margin
BLBD
BLBD
RPRX
RPRX
Q4 25
9.2%
34.4%
Q3 25
8.9%
47.3%
Q2 25
9.2%
5.2%
Q1 25
7.3%
41.9%
Q4 24
9.2%
35.1%
Q3 24
7.0%
96.3%
Q2 24
8.6%
19.0%
Q1 24
7.5%
0.8%
EPS (diluted)
BLBD
BLBD
RPRX
RPRX
Q4 25
$0.94
$0.49
Q3 25
$1.11
$0.67
Q2 25
$1.12
$0.07
Q1 25
$0.79
$0.55
Q4 24
$0.86
$0.46
Q3 24
$0.71
$1.21
Q2 24
$0.85
$0.23
Q1 24
$0.79
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLBD
BLBD
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$241.7M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$271.4M
$9.7B
Total Assets
$642.3M
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLBD
BLBD
RPRX
RPRX
Q4 25
$241.7M
$618.7M
Q3 25
$229.3M
$938.9M
Q2 25
$173.1M
$631.9M
Q1 25
$130.7M
$1.1B
Q4 24
$136.1M
$929.0M
Q3 24
$127.7M
$950.1M
Q2 24
$88.4M
$1.8B
Q1 24
$93.1M
$843.0M
Total Debt
BLBD
BLBD
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
BLBD
BLBD
RPRX
RPRX
Q4 25
$271.4M
$9.7B
Q3 25
$255.4M
$9.6B
Q2 25
$221.8M
$9.5B
Q1 25
$190.4M
$9.8B
Q4 24
$179.7M
$10.3B
Q3 24
$159.6M
$10.3B
Q2 24
$137.3M
$9.8B
Q1 24
$105.8M
$9.9B
Total Assets
BLBD
BLBD
RPRX
RPRX
Q4 25
$642.3M
$19.6B
Q3 25
$625.3M
$19.3B
Q2 25
$575.5M
$18.3B
Q1 25
$543.7M
$17.6B
Q4 24
$535.2M
$18.2B
Q3 24
$524.9M
$18.0B
Q2 24
$468.1M
$17.7B
Q1 24
$456.5M
$16.1B
Debt / Equity
BLBD
BLBD
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLBD
BLBD
RPRX
RPRX
Operating Cash FlowLast quarter
$36.6M
$827.1M
Free Cash FlowOCF − Capex
$31.1M
FCF MarginFCF / Revenue
9.3%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
1.19×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$162.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLBD
BLBD
RPRX
RPRX
Q4 25
$36.6M
$827.1M
Q3 25
$65.1M
$702.6M
Q2 25
$56.9M
$364.0M
Q1 25
$27.8M
$596.1M
Q4 24
$26.4M
$742.5M
Q3 24
$55.4M
$703.6M
Q2 24
$989.0K
$658.2M
Q1 24
$54.6M
$664.6M
Free Cash Flow
BLBD
BLBD
RPRX
RPRX
Q4 25
$31.1M
Q3 25
$60.5M
Q2 25
$52.3M
Q1 25
$18.7M
Q4 24
$21.8M
Q3 24
$50.2M
Q2 24
$-3.5M
Q1 24
$51.8M
FCF Margin
BLBD
BLBD
RPRX
RPRX
Q4 25
9.3%
Q3 25
14.8%
Q2 25
13.1%
Q1 25
5.2%
Q4 24
7.0%
Q3 24
14.3%
Q2 24
-1.1%
Q1 24
15.0%
Capex Intensity
BLBD
BLBD
RPRX
RPRX
Q4 25
1.6%
Q3 25
1.1%
Q2 25
1.2%
Q1 25
2.5%
Q4 24
1.5%
Q3 24
1.5%
Q2 24
1.3%
Q1 24
0.8%
Cash Conversion
BLBD
BLBD
RPRX
RPRX
Q4 25
1.19×
3.86×
Q3 25
1.78×
2.44×
Q2 25
1.56×
12.06×
Q1 25
1.07×
2.50×
Q4 24
0.92×
3.57×
Q3 24
2.24×
1.29×
Q2 24
0.03×
6.45×
Q1 24
2.10×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLBD
BLBD

Alternative Fuel Buses$151.4M45%
Diesel Buses$144.9M43%
Parts$24.8M7%
Other$12.1M4%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons